Cannon III RO. Restenosis after angioplasty. N Engl J Med.2002;346:1182-1183.
Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for
vascular disease: probable benefits of increasing folic acid intakes. JAMA.1995;274:1049-1057.
Seshadri N, Robinson K. Homocysteine, B vitamins, and coronary artery disease. Med Clin North Am.2000;84:215-237.
Chao CL, Tsai HH, Lee CM.
et al. The graded effect of hyperhomocysteinemia on the severity and extent
of coronary atherosclerosis. Atherosclerosis.1999;147:379-386.
Schnyder G, Pin R, Roffi M, Flammer Y, Hess OM. Association of plasma homocysteine with the number of major coronary
arteries severely narrowed. Am J Cardiol.2001;88:1027-1030.
Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary
artery disease. N Engl J Med.1997;337:230-236.
Stubbs PJ, Al-Obaidi MK, Conroy RM.
et al. Effect of plasma homocysteine concentration on early and late events
in patients with acute coronary syndromes. Circulation.2000;102:605-610.
Tsai JC, Perrella MA, Yoshizumi M.
et al. Promotion of vascular smooth muscle cell growth by homocysteine: a
link to atherosclerosis. Proc Natl Acad Sci U S A.1994;91:6369-6373.
Tang L, Mamotte CD, Van Bockxmeer FM, Taylor RR. The effect of homocysteine on DNA synthesis in cultured human vascular
smooth muscle. Atherosclerosis.1998;136:169-173.
Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent
vasodilation in humans Circulation.1997;95:1119-1121. [published correction appears in Circulation. 2000;101:E116].
Woo KS, Chook P, Lolin YI.
et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction
in humans. Circulation.1997;96:2542-2544.
Wang XL, Duarte N, Cai H.
et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine
metabolism related enzymes, risk factors and coronary artery disease in the
Australian hospital-based population. Atherosclerosis.1999;146:133-140.
Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular
endothelial cell activator. J Clin Invest.1986;77:1909-1916.
Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation
by arterial and venous endothelial cells. Blood.1990;75:895-901.
Hajjar KA, Mauri L, Jacovina AT.
et al. Tissue plasminogen activator binding to the annexin II tail domain:
direct modulation by homocysteine. J Biol Chem.1998;273:9987-9993.
Khajuria A, Houston DS. Induction of monocyte tissue factor expression by homocysteine: a possible
mechanism for thrombosis. Blood.2000;96:966-972.
Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Association of plasma homocysteine with restenosis after percutaneous
coronary angioplasty. Eur Heart J.2002;23:726-733.
Morita H, Kurihara H, Kuwaki T.
et al. Homocysteine as a risk factor for restenosis after coronary angioplasty. Thromb Haemost.2000;84:27-31.
Schnyder G, Roffi M, Pin R.
et al. Decreased rate of coronary restenosis with lowering of plasma homocysteine
levels. N Engl J Med.2001;345:1593-1600.
Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis
of randomised trials. BMJ.1998;316:894-898.
Ubbink JB, Hayward-Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine
levels in human serum. J Chromatogr.1991;565:441-446.
TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med.1985;312:932-936.
Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous
outcomes in two group comparisons. BMJ.1995;311:1145-1148.
Ellis SG, Vandormael MG, Cowley MJ.
et al. Coronary morphologic and clinical determinants of procedural outcome
with angioplasty for multivessel coronary disease: implications for patient
Hirshfeld Jr JW, Schwartz JS, Jugo R.
et al. Restenosis after coronary angioplasty: a multivariate statistical model
to relate lesion and procedure variables to restenosis. J Am Coll Cardiol.1991;18:647-656.
Ellis SG, Cowley MJ, DiSciascio G.
et al. Determinants of 2-year outcome after coronary angioplasty in patients
with multivessel disease on the basis of comprehensive preprocedural evaluation:
implications for patient selection. Circulation.1991;83:1905-1914.
Vermeulen EGJ, Stehouwer CDA, Twisk JWR.
et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin
B6 on progression of subclinical atherosclerosis: a randomised,
placebo-controlled trial. Lancet.2000;355:517-522.
Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? effects of vitamin
therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine
levels above and below 14 µmol/L. Am J Hypertens.2000;13:105-110.
Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol.1999;34:2002-2006.
Title LM, Cummings PM, Giddens K, Genest JJ, Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction
in patients with coronary artery disease. J Am Coll Cardiol.2000;36:758-765.
Doshi SN, McDowell IFW, Moat SJ.
et al. Folate improves endothelial function in coronary artery disease: an
effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol.2001;21:1196-1202.
Mangoni AA, Jackson SHD. Homocysteine and cardiovascular disease: current evidence and future
prospects. Am J Med.2002;112:556-565.
Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen
production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol.1997;17:2074-2081.
Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation
from homocysteine. J Clin Invest.1986;77:1370-1376.
Upchurch Jr GR, Welch GN, Fabian AJ.
et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving
glutathione peroxidase. J Biol Chem.1997;272:17012-17017.
Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric
Voutilainen S, Morrow JD, Roberts II LJ.
et al. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine
levels. Arterioscler Thromb Vasc Biol.1999;19:1263-1266.
Ku G, Doherty NS, Wolos JA, Jackson LR. Inhibition by probucol of interleukin 1 secretion and its implication
in atherosclerosis. Am J Cardiol.1988;62:77B-81B.
Cushing SD, Berliner JA, Valente AJ.
et al. Minimally modified low density lipoprotein induces monocyte chemotactic
protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A.1990;87:5134-5138.
Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant
protein-1 and interleukin-8 in human aortic endothelial cells: implications
for vascular disease. Circulation.2001;103:2717-2723.
Stiko-Rahm A, Hultgardh-Nilsson A, Regnstrom J, Hamsten A, Nilsson J. Native and oxidized LDL enhances production of PDGF AA and the surface
expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler Thromb.1992;12:1099-1109.
Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial
function in familial hypercholesterolemia. Circulation.1998;97:237-241.
Robinson K, Arheart K, Refsum H.
et al. Low circulating folate and vitamin B6 concentrations: risk factors
for stroke, peripheral vascular disease, and coronary artery disease. Circulation.1998;97:437-443.
[published correction appears in Circulation. 1999;99:983].
Krishnamurthi S, Kakkar VV. Studies on the effect of platelet inhibitors on platelet adhesion to
collagen and collagen-induced human platelet activation. Thromb Haemost.1985;53:337-342.